Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30681309 | 1.00 | TRPM5 (0.43) | TRPM5GAAMAPTCREBBPBRD4 | |
| SCHEMBL5336233 | 1.00 | TRPM5 (0.43) | TRPM5GAAMAPTCREBBPBRD4 | |
| SCHEMBL30681274 | 1.00 | TRPM5 (0.43) | TRPM5GAAMAPTCREBBPBRD4 | |
| SCHEMBL13384188 | 0.83 | MTNR1A (0.52) | TRPM5GAAMAPTCREBBPBRD4 | |
| SCHEMBL2259545 | 0.83 | GAA (0.40) | GAAMAPTCREBBPBRD4MTNR1A | |
| SCHEMBL549073 | 0.79 | CREBBP (0.59) | GAAMAPTCREBBPBRD4MTNR1A | |
| SCHEMBL22955423 | 0.79 | CREBBP (0.59) | GAAMAPTCREBBPBRD4MTNR1A | |
| SCHEMBL5336646 | 0.79 | GAA (0.44) | GAAMAPT | |
| SCHEMBL5336642 | 0.79 | GAA (0.44) | GAAMAPT | |
| SCHEMBL30681246 | 0.78 | GAA (0.39) | GAAMAPTCREBBPBRD4MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024024935-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE HAVING ANTINEOPLASTIC EFFECT | 第一三共株式会社 | 2024-02-01 | — | — | WO | disclosed |
| CN-110437123-B | Method for synthesizing optically pure 2-substituted indoline compound through dynamic kinetic resolution | 华中师范大学 | 2023-01-03 | — | — | CN | disclosed |
| US-8993565-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2015-03-31 | — | — | US | disclosed |
| US-20140303156-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-10-09 | — | — | US | disclosed |
| US-8791255-B2 | (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors | SANOFI (FR) | 2014-07-29 | — | — | US | disclosed |
| EP-2448927-B1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012163898-A1 | DYE COMPOSITION USING A (HYDROXY)INDOLINE COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESS AND DEVICES | L'OREAL (FR) | 2012-12-06 | — | — | WO | disclosed |
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| CN-102548970-A | Novel (6-oxo-1, 6-dihydropyrimidin-2-yl) amide derivatives, process for their preparation and their medical use as akt (pkb) phosphorylation inhibitors | SANOFI AVENTIS | 2012-07-04 | — | — | CN | disclosed |
| EP-2448927-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011001114-A1 | NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI-AVENTIS (FR) | 2011-01-06 | — | — | WO | disclosed |
| US-20070270587-A1 | PYRIMIDOINDOLONES AND METHODS FOR USING SAME | WYETH (US) | 2007-11-22 | — | — | US | disclosed |
| US-7256198-B2 | Pyrimidoindolones and methods for using same | WYETH (US) | 2007-08-14 | — | — | US | disclosed |
| US-20050250798-A1 | E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke | WYETH (US) | 2005-11-10 | — | — | US | disclosed |
| WO-2001074771-A1 | PYRROLE-2,5-DIONE DERIVATIVES FOR THE TREATMENT OF DIABETES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270867-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | AKT1, AKT2, MTOR | TRPM5 4242/4885GAA 1036/4885MAPT 3820/4885 |
| US-20070270587-A1 | PYRIMIDOINDOLONES AND METHODS FOR USING SAME | TYMP, DPYD, TYMS | TRPM5 3915/4885GAA 788/4885MAPT 1346/4885 |
| US-20050250798-A1 | E.g., 8-{[(2S)-2-(Methoxymethyl)pyrrolidin-1-yl]sulfonyl}-3,4-dihydropyrimido[1,2-a]indol-10(2H)-one; caspase inhibitors used to treat diseases including arthritis, myocardial infarction or stroke | CASP1, API5, CASP8 | TRPM5 3576/4885GAA 566/4885MAPT 1714/4885 |
| US-20140303156-A1 | NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | AKT1, AKT2, MTOR | TRPM5 4242/4885GAA 1036/4885MAPT 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.